AU2002316191A1 - Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists - Google Patents
Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonistsInfo
- Publication number
- AU2002316191A1 AU2002316191A1 AU2002316191A AU2002316191A AU2002316191A1 AU 2002316191 A1 AU2002316191 A1 AU 2002316191A1 AU 2002316191 A AU2002316191 A AU 2002316191A AU 2002316191 A AU2002316191 A AU 2002316191A AU 2002316191 A1 AU2002316191 A1 AU 2002316191A1
- Authority
- AU
- Australia
- Prior art keywords
- naphthaline
- oxyquinoline
- piperazine
- receptor antagonists
- adenosine diphosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 title 1
- 229960003540 oxyquinoline Drugs 0.000 title 1
- 239000000719 purinergic P2Y receptor antagonist Substances 0.000 title 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29649801P | 2001-06-06 | 2001-06-06 | |
| US60/296,498 | 2001-06-06 | ||
| US10/163,742 | 2002-06-05 | ||
| US10/163,742 US6861424B2 (en) | 2001-06-06 | 2002-06-05 | Platelet adenosine diphosphate receptor antagonists |
| PCT/US2002/017821 WO2002098856A2 (en) | 2001-06-06 | 2002-06-06 | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002316191A1 true AU2002316191A1 (en) | 2002-12-16 |
Family
ID=26859907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002316191A Abandoned AU2002316191A1 (en) | 2001-06-06 | 2002-06-06 | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US6861424B2 (https=) |
| EP (1) | EP1412349A2 (https=) |
| JP (1) | JP4409936B2 (https=) |
| AU (1) | AU2002316191A1 (https=) |
| WO (1) | WO2002098856A2 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| WO2003059884A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
| OA12970A (en) * | 2002-12-11 | 2006-10-13 | Schering Ag | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists. |
| WO2005009971A1 (ja) * | 2003-07-24 | 2005-02-03 | Astellas Pharma Inc. | キノロン誘導体又はその塩 |
| CN101031565B (zh) * | 2004-09-29 | 2010-09-29 | 博尔托拉制药公司 | 取代的2h-1,3-苯并噁嗪-4(3h)-酮 |
| TW200640877A (en) * | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| WO2007016539A2 (en) * | 2005-07-29 | 2007-02-08 | Children's Hospital Medical Center | Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase |
| JP4976394B2 (ja) * | 2005-08-17 | 2012-07-18 | シェーリング コーポレイション | 新規な高親和性のキノリンベースのキナーゼリガンド |
| WO2007046075A1 (en) * | 2005-10-21 | 2007-04-26 | Actelion Pharmaceuticals Ltd | Piperazine derivatives as antimalarial agents |
| US7615556B2 (en) * | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
| TWI391378B (zh) | 2006-03-16 | 2013-04-01 | Astellas Pharma Inc | 喹啉酮衍生物或其製藥學上可被容許之鹽 |
| JP2009534310A (ja) * | 2006-03-29 | 2009-09-24 | 武田薬品工業株式会社 | レニン阻害剤 |
| US20070254861A1 (en) * | 2006-04-28 | 2007-11-01 | Astellas Pharma Inc. | Methods for the prevention and/or treatment of peripheral arterial disease |
| AR063258A1 (es) | 2006-10-13 | 2009-01-14 | Actelion Pharmaceuticals Ltd | Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos. |
| AR063518A1 (es) * | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
| EP1967513A1 (en) * | 2007-03-08 | 2008-09-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel P2Y12 receptor antagonists |
| KR20100015886A (ko) * | 2007-04-23 | 2010-02-12 | 사노피-아벤티스 | Ｐ2ｙ12 길항제로서의 퀴놀린-카복스아미드 유도체 |
| CN101679358B (zh) | 2007-06-18 | 2013-10-30 | 塞诺菲-安万特股份有限公司 | 作为p2y12拮抗剂的吡咯衍生物 |
| ES2388958T3 (es) * | 2007-11-29 | 2012-10-22 | Actelion Pharmaceuticals Ltd. | Derivados de acido fosfonico y su uso como antagonista del receptor P2Y12 |
| EP2238128B1 (en) * | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
| AR071653A1 (es) * | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| US20130303477A1 (en) | 2008-05-13 | 2013-11-14 | The Medicines Company | Maintenance of Platelet Inhibition During Antiplatelet Therapy |
| US8759316B2 (en) | 2008-05-13 | 2014-06-24 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| WO2009140092A1 (en) | 2008-05-13 | 2009-11-19 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
| US9427448B2 (en) | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| US20120141468A1 (en) | 2008-05-13 | 2012-06-07 | Lisa Ruderman Chen | Maintenance of platelet inhibition during antiplatelet therapy |
| WO2010075356A1 (en) * | 2008-12-23 | 2010-07-01 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
| KR101694563B1 (ko) | 2009-04-08 | 2017-01-09 | 액테리온 파마슈티칼 리미티드 | Ａｄｐ 수용체 길항제로서 6-(3-아자-비시클로〔3.1.0〕헥스-3-일)-2-페닐-피리미딘 |
| EP2421859B1 (en) | 2009-04-22 | 2014-04-09 | Actelion Pharmaceuticals Ltd. | Thiazole derivatives and their use as p2y12 receptor antagonists |
| ES2470329T3 (es) | 2009-08-28 | 2014-06-23 | Daiichi Sankyo Company, Limited | Derivado del ácido 3-(biariloxi) priopi�nico |
| US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| PT2498731T (pt) | 2009-11-11 | 2020-02-21 | Chiesi Farm Spa | Métodos de tratamento ou prevenção de uma trombose de endoprótese |
| JP2013512246A (ja) | 2009-11-25 | 2013-04-11 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体 |
| US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
| US8889688B2 (en) | 2010-01-05 | 2014-11-18 | Actelion Pharmaceuticals Ltd. | Piperazines as antimalarial agents |
| EA201290882A1 (ru) | 2010-03-09 | 2013-04-30 | Мерк Шарп Энд Домэ Корп. | Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний |
| US20140378416A1 (en) | 2011-09-14 | 2014-12-25 | Michael P. Dwyer | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| GB201218084D0 (en) * | 2012-10-09 | 2012-11-21 | Univ Aston | Novel compounds and methods for use in medicine |
| CA2901920A1 (en) | 2013-03-15 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Novel acrylamide derivatives as antimalarial agents |
| HUE057772T2 (hu) | 2016-09-22 | 2022-06-28 | Idorsia Pharmaceuticals Ltd | Kristályos formák |
| US11179390B2 (en) | 2017-03-15 | 2021-11-23 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a P2Y12 receptor antagonist |
| US11260071B2 (en) | 2017-06-23 | 2022-03-01 | Chiesi Farmaceutici S.P.A. | Method of preventing of systemic-to-pulmonary-artery shunt thrombosis |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| EP4031542B1 (en) * | 2019-09-18 | 2025-10-15 | Merck Sharp & Dohme LLC | Small molecule inhibitors of kras g12c mutant |
| CN114867726B (zh) | 2019-10-28 | 2023-11-28 | 默沙东有限责任公司 | Kras g12c突变体的小分子抑制剂 |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| US11945790B2 (en) * | 2020-12-22 | 2024-04-02 | Immunomolecular Therapeutics, Inc. | Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2 |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1334705A (en) | 1970-06-19 | 1973-10-24 | Ici Ltd | Pharmaceutical compositions containing kynurenic acid derivatives |
| US4258192A (en) | 1977-12-16 | 1981-03-24 | Mitsubishi Chemical Industries Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US5346907A (en) | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
| CA2073776A1 (en) | 1990-11-15 | 1992-05-16 | Joerg Stuerzebecher | Meta-substituted phenyl alanine derivatives |
| JPH07509731A (ja) | 1993-02-10 | 1995-10-26 | ペンタファルム アクチェンゲゼルシャフト | トロンビン阻害剤としての置換されたフェニルアラニン誘導体のピペラジド |
| KR0173034B1 (ko) | 1995-04-28 | 1999-03-30 | 성재갑 | 선택적 트롬빈 억제제 |
| US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
| DE60022508T2 (de) * | 1999-06-14 | 2006-06-08 | Eli Lilly And Co., Indianapolis | Inhibitoren von serin proteasen |
-
2002
- 2002-06-05 US US10/163,742 patent/US6861424B2/en not_active Expired - Fee Related
- 2002-06-06 AU AU2002316191A patent/AU2002316191A1/en not_active Abandoned
- 2002-06-06 EP EP02746471A patent/EP1412349A2/en not_active Withdrawn
- 2002-06-06 JP JP2003501845A patent/JP4409936B2/ja not_active Expired - Fee Related
- 2002-06-06 WO PCT/US2002/017821 patent/WO2002098856A2/en not_active Ceased
-
2004
- 2004-09-22 US US10/947,579 patent/US7026323B2/en not_active Expired - Fee Related
- 2004-09-22 US US10/947,635 patent/US6995156B2/en not_active Expired - Fee Related
-
2006
- 2006-02-02 US US11/347,768 patent/US7176207B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002098856A3 (en) | 2004-03-04 |
| US6995156B2 (en) | 2006-02-07 |
| JP4409936B2 (ja) | 2010-02-03 |
| US20050038037A1 (en) | 2005-02-17 |
| US20030060474A1 (en) | 2003-03-27 |
| US6861424B2 (en) | 2005-03-01 |
| US7176207B2 (en) | 2007-02-13 |
| JP2004532886A (ja) | 2004-10-28 |
| WO2002098856A2 (en) | 2002-12-12 |
| US20050065163A1 (en) | 2005-03-24 |
| US20060135532A1 (en) | 2006-06-22 |
| EP1412349A2 (en) | 2004-04-28 |
| US7026323B2 (en) | 2006-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002316191A1 (en) | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists | |
| IL150912A0 (en) | Adenosine receptor modulators | |
| AU2002341834A1 (en) | Antagonists | |
| GB2378087B (en) | Multi-site responsibility-based routing | |
| IL161716A0 (en) | ADENOSINE A2a RECEPTOR ANTAGONISTS | |
| AU6690001A (en) | Thrombin receptor antagonists | |
| AU6808901A (en) | Adenosine a2a receptor antagonists | |
| IL161572A0 (en) | Adenosine a2a receptor antagonists | |
| AU2002367366A1 (en) | System for communicating through maps | |
| AU2875999A (en) | Antagonists of a2b human adenosine receptors | |
| AU2002346048A1 (en) | Benzodiazepine bradykinin antagonists | |
| PL373953A1 (en) | 7-amino-benzothiazole derivatives as adenosine receptor ligands | |
| PL377053A1 (pl) | Związki 2-aminokarbonylo-chinoliny jako antagonisty receptora płytkowego difosforanu adenozyny | |
| AUPR279101A0 (en) | Protein kinase signalling | |
| IL160715A0 (en) | Pharmaceutical compositions containing an a1 adenosine receptor antagonist | |
| IL162444A (en) | Triazolo-quinolin derivatives useful as adenosine receptor ligands | |
| AU3167402A (en) | Aminotriazolopyridiine derivatives as adenosine receptor ligands | |
| AU2002359524A1 (en) | P2x7 receptor antagonists | |
| AU2001249573A1 (en) | Chemokine receptor antagonists | |
| HK1064382A (en) | Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists | |
| IL156087A0 (en) | Histamine receptor antagonists | |
| AU4121601A (en) | Bridge seat construction | |
| AU2002328569A1 (en) | Medicinal compositions containing angiotensin II receptor antagonist | |
| HK1083750A (en) | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists | |
| AU2002319728A1 (en) | Platelet adp receptor inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |